Genetic polymorphism CYP2C19 and its relation to pharmacokinetics and acid-suppression effect of proton pump inhibitors

被引：0
|
作者：
Niu, CY
Luo, JY
机构：
来源：
GASTROENTEROLOGY | 2004年 / 126卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A536 / A536
页数：1
相关论文
共 50 条
  • [21] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    H. Katsuki
    C. Nakamura
    K. Arimori
    S. Fujiyama
    M. Nakano
    European Journal of Clinical Pharmacology, 1997, 52 : 391 - 396
  • [22] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    Katsuki, H
    Nakamura, C
    Arimori, K
    Fujiyama, S
    Nakano, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) : 391 - 396
  • [23] Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem
    Klotz, U.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2006, 44 (07) : 297 - 302
  • [24] CYP2C19 polymorphism and proton pump inhibitors (PPI) in Helicobacter pylori eradication therapy - A metaanalysis
    Treiber, GG
    Schwab, M
    Klotz, U
    GASTROENTEROLOGY, 2004, 126 (04) : A603 - A603
  • [25] Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem
    Padol, S.
    Yuan, Y.
    Thabane, M.
    Padol, I. T.
    Hunt, R. H.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (03) : 188 - 188
  • [26] Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
    El Rouby, Nihal
    Lima, John J.
    Johnson, Julie A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (04) : 447 - 460
  • [27] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Cho, Chang-Keun
    Byeon, Ji-Young
    Kang, Pureum
    Park, Hye-Jung
    Ko, Eunvin
    Mu, Chou Yen
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (02) : 111 - 116
  • [28] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Chang‑Keun Cho
    Ji-Young Byeon
    Pureum Kang
    Hye-Jung Park
    Eunvin Ko
    Chou Yen Mu
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Archives of Pharmacal Research, 2023, 46 : 111 - 116
  • [29] Effect of CYP2C19*2 and*17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians
    Hunfeld, Nicole G.
    Mathot, Ron A.
    Touw, Daan J.
    van Schaik, Ron H.
    Mulder, Paul G.
    Franck, Paul F.
    Kuipers, Ernst J.
    Geus, William P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) : 752 - 760
  • [30] Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review
    Ibrahim, Asmaa
    Yusuff, Kazeem
    Awaisu, Ahmed
    Elewa, Hazem
    FRONTIERS IN PHARMACOLOGY, 2025, 16
12345